Table 2. Healthy controls (HC) demographics and NLV expansion profiles.
| NLV-specific CD8+ T cells | |||||
| HC | HLA-A or -A* | HLA-B or -B* | CMV serology | % Ex vivo | % In vitro |
| HC1 | 2 | 51, 61 | − | NT | 0.2 |
| HC2 | 2, 3 | 14, 27 | − | NT | 0.1 |
| HC3 | 2, 24 | 07:02, 56:01 | + | 0.1 | 23.4 |
| HC4 | 02:01 | 15, 44:02 | + | 1.2 | 90.5 |
| HC5 | 02:01, 11 | 51, 61 | + | 0.1 | 69.9 |
| HC6 | 1, 02:01 | 07:02, 44:02 | + | NT | 9.1 |
| HC7 | 1, 2 | 08:01, 44:03 | + | NT | 14 |
| HC8 | 02:01, 29:02 | 07:02, 44:03 | + | NT | 37.6 |
| HC9 | 2 | 8, 62 | + | NT | 97.2 |
| HC10 | 2 | 8, 57 | + | NT | 93.2 |
| HC11 | 2, 32 | 35, 44 | + | NT | 65.95 |
| HC12 | 2, 3 | 8, 18 | + | 2.1 | 16.3 |
| HC13 | 2, 3 | 7, 8 | + | 1 | 0.4 |
| HC14 | 02:01, 03:01 | 07:02, 45:01 | + | 1.4 | 0.2 |
| Average | 1.0 | 43.2 | |||
| ±SD | 0.8 | 35.6 | |||
| Range | 0.1–2.1 | 0.2–97.2 | |||
HLA class I typing, CMV serology status and NLV-specific T cell expansion profiles of healthy individuals. Molecular resolution of HLA class I antigens was available as indicated (4-digit). In vitro T cell cultures were derived by autologous stimulation of PBMC with NLV peptide (1 µM) for 13 days in the presence of IL-2 (20 U/ml). Percentages of A2/NLV-tetramer+ T cells were based on the total CD8+ T cell population. HC1 and 2 were excluded from the average, SD and range calculations.
Abbreviation: not tested (NT).